Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Autor: Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Patrice Rodien, Barbara Jarzab, Domenico Salvatore, Sylvie Zanetta, Jaume Capdevila, Lars Bastholt, Christelle De La Fouchardiere, Yassine Lalami, Stéphane Bardet, Frank Cornélis, Marek Dedecjus, Thera Links, Ward Sents, Martin Schlumberger, D. Laura Locati, Katie Newbold

Publikováno v: Frontiers in Endocrinology, Vol 15 (2024)

BackgroundNintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC).DesignEORTC-1209 (NCT01788

Externí odkaz: https://doaj.org/article/6cb94876a3044358996b174c5e0cfcd4

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report

Autor: Romain Varnier, Thibaut Garrivier, Emilie Hafliger, Aymeric Favre, Clélia Coutzac, Clément Spire, Pauline Rochefort, Matthieu Sarabi, Françoise Desseigne, Pierre Guibert, Anne Cattey-Javouhey, Pamela Funk-Debleds, Charles Mastier, Adrien Buisson, David Pérol, Oliver Trédan, Jean-Yves Blay, Jean-Marc Phelip, Christelle de la Fouchardiere

Publikováno v: Frontiers in Oncology, Vol 11 (2021)

Immune checkpoint inhibitors (ICI) have been developed in gastric adenocarcinomas and approved in first-line metastatic setting (in combination with chemotherapy) as well as in pretreated patients. Microsatellite instability-high (MSI-H) tumors are p

Externí odkaz: https://doaj.org/article/2224c227c53b4b719b18694921a201c0

Outcome of adrenocortical carcinoma patients included in early phase clinical trials: results from the French network ENDOCAN-COMETE

Autor: Ségolène Hescot, Véronique Debien, Julien Hadoux, Delphine Drui, Magalie Haissaguerre, Christelle de la Fouchardiere, Delphine Vezzosi, Christine Do Cao, Rossella Libé, Christophe Le Tourneau, Eric Baudin, Christophe Massard, Pauline du Rusquec

Publikováno v: European Journal of Cancer.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32521ffb24611f5a547f689ceb9972d7
https://doi.org/10.1016/j.ejca.2023.05.006

Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon

Autor: Aurelien Marabelle, Sylvie Chevret, Pierre Saintigny, Luis A. Diaz, Assia Lamrani-Ghaouti, Clotilde Simon, Frederic Legrand, Natalie Hoog-Labouret, Andrea Cercek, Neil H. Segal, Anthony Ferrari, Severine Tabone-Eglinger, Asha R. Krishnan, Guillem Argiles, Bill H. Diplas, Steven B. Maron, Michelle F. Lamendola-Essel, Dennis Stephens, Drew G. Gerber, Stephane Champiat, Jean-Charles Soria, Christophe Tournigand, Stephane Oudard, Farid El Hajbi, Diane Pannier, Thierry Andre, Olivier Bouche, Esma Saada-Bouzid, Sandrine Hiret, Frederic Rolland, Aude Flechon, Christelle de la Fouchardiere, Sophie Cousin, Muriel Duluc, Jean-Jacques Grob, Marielle Guillet, Amandine Bruyas, Rosine Guimbaud, Carlos Gomez-Roca, Damien Pouessel, Antoine Hollebecque, David Malka, Paule Augereau, Victor Simmet, Romain Cohen, Magali Svrcek, Julien Masliah-Planchon, Michael B. Foote, Valerie Attignon, Aurelien de Reynies, Lucas Michon, Nicolas Leulliot, Nadim Hamzaoui, Eric Pasmant, Ivan Bieche, Benoit Rousseau

Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a66d609cc79fa4d01bedd59b08afcf
https://doi.org/10.1158/2159-8290.22541062

Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181

Autor: Jean-Philippe Metges, Mayur Amonkar, Christelle De La Fouchardiere, Amit S. Kulkarni, Wasat Mansoor, Antoine Adenis, Raed Al-Rajabi, Pooja Bhagia, Hanneke W. M. van Laarhoven, Shailaja Suryawanshi, Josephine M. Norquist, Gustavo Girotto, Hélène Senellart

Publikováno v: Journal of clinical oncology, 40(4), 382-391. American Society of Clinical Oncology
Adenis, A, Kulkarni, A S, Girotto, G C, de la Fouchardiere, C, Senellart, H, van Laarhoven, H W M, Mansoor, W, Al-Rajabi, R, Norquist, J, Amonkar, M, Suryawanshi, S, Bhagia, P & Metges, J-P 2022, ' Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 4, pp. 382-391 . https://doi.org/10.1200/JCO.21.00601
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(4), 382-391. American Society of Clinical Oncology

PURPOSE In the phase III KEYNOTE-181 study ( NCT02564263 ) of patients with advanced esophageal cancer (EC), pembrolizumab monotherapy prolonged overall survival versus chemotherapy as second-line therapy in patients with programmed death ligand 1 co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79dfe3fd0174abb2c97536677cb41ddf
http://www.scopus.com/inward/record.url?scp=85123901600&partnerID=8YFLogxK